Comparative Pharmacology
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELFLEX W DEXTROSE 4 25 LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER versus DELFLEX LM W DEXTROSE 1 5 IN PLASTIC CONTAINER.
DELFLEX W/ DEXTROSE 4.25% LOW MAGNESIUM LOW CALCIUM IN PLASTIC CONTAINER vs DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Delflex with 4.25% dextrose is a peritoneal dialysis solution that removes waste products, electrolytes, and excess fluid from the blood via diffusion and ultrafiltration across the peritoneal membrane. Dextrose creates an osmotic gradient, drawing fluid and solutes from the capillaries into the peritoneal cavity.
Removes waste products (e.g., urea, creatinine) and excess fluid from the blood through peritoneal dialysis by diffusion and osmosis across the peritoneal membrane.
Continuous ambulatory peritoneal dialysis (CAPD)Continuous cycling peritoneal dialysis (CCPD)Automated peritoneal dialysis (APD)Management of end-stage renal disease (ESRD)
Treatment of acute and chronic renal failureManagement of end-stage renal disease (ESRD)
Intraperitoneal administration: 2 to 2.5 liters per exchange, 4 to 5 exchanges per day, as part of continuous ambulatory peritoneal dialysis (CAPD).
Intraperitoneal administration: 2 liters per exchange, 4 exchanges daily; dwell time 4-6 hours; concentration selected based on ultrafiltration needs.
None Documented
None Documented
Not applicable as a combination solution; glucose half-life ~1.5-2 hours in normal renal function; prolonged in renal impairment.
The terminal half-life of icodextrin (as total icodextrin-derived oligosaccharides) is approximately 5-8 hours after a single dwell, reflecting clearance from the plasma compartment. Clinically, sustained levels can occur with repeated exchanges.
Dextrose is absorbed systemically and metabolized via glycolysis and the Krebs cycle. No hepatic metabolism for the solution components; waste removal is achieved through peritoneal dialysis. Insulin may be required to manage hyperglycemia.
Dextrose is metabolized via glycolysis; lactate is converted to bicarbonate in the liver. No significant hepatic metabolism for electrolyte components.
Renal: >90% as unchanged glucose and electrolytes; negligible biliary/fecal elimination.
Delflex-LM with Dextrose 1.5% (icodextrin) is a peritoneal dialysis solution. Icodextrin is metabolized to oligosaccharides and primarily eliminated via the peritoneal cavity during dialysis. Renal excretion is minimal (<1%). The majority of icodextrin and its metabolites are removed with the dialysate effluent.
Minimal (<10%); glucose and electrolytes do not significantly bind to plasma proteins.
Icodextrin and its metabolites are minimally protein-bound (<5%), primarily to albumin.
Glucose: ~0.2 L/kg (extracellular fluid); electrolytes distribute according to body water compartments.
The apparent volume of distribution (Vd) for icodextrin-derived oligosaccharides is approximately 0.1-0.2 L/kg, reflecting distribution mainly in the extracellular fluid and limited distribution into cells.
Intraperitoneal: ~70-80% for glucose absorption; electrolytes 100% bioavailable via peritoneal route.
Bioavailability: Not applicable for the intraperitoneal route (100% exposure to peritoneal cavity). For systemic absorption, 60-70% of the administered icodextrin dose is absorbed across the peritoneum into the systemic circulation during a dwell, but this is not a standard bioavailability measure.
Not applicable; drug is used for renal replacement therapy in end-stage renal disease.
No dose adjustment required for renal impairment as drug is administered intraperitoneally for peritoneal dialysis.
No specific adjustments; monitor for metabolic acidosis and electrolyte imbalances in severe hepatic impairment.
No specific pediatric dosing available; use adult dosing with caution and monitor for signs of fluid overload or electrolyte imbalance.
Weight-based: 30 to 40 mL/kg per exchange, 4 to 5 exchanges per day; adjust based on residual renal function and ultrafiltration needs.
Individualized based on body weight: typical starting volume 30-40 mL/kg per exchange, 4-5 exchanges daily; adjust to achieve adequate ultrafiltration and solute clearance.
No specific dose adjustments; monitor glucose and electrolyte levels closely due to higher risk of hyperglycemia and fluid overload.
Use same dosing as younger adults; monitor fluid and electrolyte status closely due to increased risk of fluid overload and electrolyte disturbances.
Peritoneal dialysis solutions with dextrose, including Delflex with 4.25% dextrose, are contraindicated in patients with pre-existing severe hyperglycemia or who are hypersensitive to any component of the product. The solution is for peritoneal administration only, not for intravenous use. Strict sterile technique in catheter placement and fluid exchange is required to prevent peritonitis.
Not for intravenous use. Use only for intraperitoneal administration.
["Hyperglycemia and hyperosmolar syndrome, especially in patients with diabetes mellitus","Peritonitis and exit-site infections; strict aseptic technique required","Electrolyte imbalances (hypokalemia, hypomagnesemia, hypocalcemia) due to low magnesium and low calcium formulation","Protein loss and malnutrition","Fluid overload or dehydration (monitor fluid balance)","Hernias and abdominal discomfort","Peritoneal catheter complications"]
["Monitor for peritonitis, electrolyte imbalances, and fluid overload","Use with caution in patients with severe hyperglycemia or lactic acidosis","Mechanical complications (e.g., catheter malfunction, leakage) may occur"]
["Hypersensitivity to any component","Pre-existing severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions, fibrosis, or sclerosis","Abdominal wall infection or peritonitis","Recent abdominal surgery or trauma","Severe pulmonary disease (risk of respiratory compromise)","Collagen vascular disease (e.g., scleroderma)","Uncorrectable mechanical defects (e.g., catheter malfunction)"]
["Severe hyperglycemia or uncontrolled diabetes","Peritoneal adhesions or fibrosis compromising membrane function","Active intra-abdominal infection or peritonitis","Pre-existing severe lactic acidosis","Hypersensitivity to any component"]
Data Pending Review
Data Pending Review
No direct food interactions, but patients on peritoneal dialysis may require dietary restrictions for potassium, phosphorus, and sodium. Avoid excessive intake of calcium- or magnesium-rich foods (e.g., dairy, nuts, leafy greens) if monitoring indicates imbalances. Dextrose absorption may affect blood glucose; manage carbohydrate intake accordingly.
["Avoid foods high in potassium (e.g., bananas, oranges, potatoes, tomatoes) unless dietary potassium is restricted per renal diet.","Limit intake of phosphorus-rich foods (e.g., dairy, nuts, beans) to manage hyperphosphatemia.","Restrict sodium intake to control fluid retention and blood pressure as advised by renal diet.","Maintain adequate protein intake as prescribed, typically 1.2-1.5 g/kg/day.","Monitor fluid intake as per individual dry weight and ultrafiltration goals.","Avoid grapefruit juice as it may affect drug metabolism (relevant only if concomitant medications are affected)."]
Delflex w/ Dextrose 4.25% Low Magnesium Low Calcium is a peritoneal dialysis solution. There are no adequate studies in pregnant women. Peritoneal dialysis itself may pose risks (e.g., infection, preterm labor). Dextrose may cause maternal hyperglycemia and fetal hyperinsulinism. Use only if clearly needed, weighing risks vs benefits. Trimester-specific risks are not established; reports of congenital anomalies are not directly attributed to the solution.
No known teratogenic effects in humans; intraperitoneal administration of dialysis solutions during pregnancy may cause maternal fluid and electrolyte disturbances that secondarily affect the fetus. Use only if clearly needed.
It is unknown whether Delflex components are excreted in human milk. Dextrose and electrolytes are endogenous substances. The M/P ratio is not available. Caution is advised; consider risk of infant exposure to small amounts of dialysate components.
Excreted into breast milk in negligible amounts; M/P ratio not established. Compatible with breastfeeding.
No specific dose adjustment recommendations during pregnancy. Pharmacokinetic changes (e.g., increased volume of distribution, altered electrolyte needs) may require careful monitoring and adjustment of exchange volume, frequency, and electrolyte composition to maintain metabolic control. Consult nephrology for individualized therapy.
No specific dose adjustment recommended; monitor for volume overload and electrolyte imbalances due to increased plasma volume in pregnancy.
Category C
Category C
This solution is used in peritoneal dialysis. The low magnesium and low calcium formulation is indicated for patients with hypermagnesemia or hypercalcemia, or to adjust electrolyte balance. Monitor serum magnesium and calcium levels regularly. The 4.25% dextrose concentration provides higher ultrafiltration; use with caution in patients with hyperglycemia or insulin-dependent diabetes. Check for solution cloudiness or leaks before use. Warm solution to body temperature before infusion to reduce discomfort.
Continuous ambulatory peritoneal dialysis (CAPD) solution; verify glucose concentration (1.5%) and correct patient before use; warm to body temperature prior to instillation to reduce discomfort; check for cloudiness, discoloration, or leaks before administration; monitor effluent for clarity and volume; adjust dwell time based on ultrafiltration needs; use sterile technique for connection and disconnection.
Follow strict sterile technique during bag exchange to prevent peritonitis.Check the solution for clarity, color, and leaks before use.Warm the solution to body temperature before infusion for comfort.Monitor for signs of infection (abdominal pain, fever, cloudy effluent) and report immediately.Keep a log of your weight, blood pressure, and inflow/outflow volumes.Do not modify the solution composition without consulting your healthcare provider.
Wash hands thoroughly before handling the solution.Inspect the solution bag for any cloudiness, particles, or leaks before use; do not use if present.Warm the solution to body temperature by placing it on a warmer or using body heat, not in boiling water or microwave.Use strict sterile technique when connecting and disconnecting the solution to prevent infection.Record the volume of effluent drained and report any significant decrease or cloudy appearance to your healthcare provider.Follow the prescribed dwell time and exchange schedule exactly as directed.Do not reuse any of the solution or tubing; all components are for single use only.Store unused bags at room temperature away from direct sunlight and heat.